|Videos|December 24, 2019
HER2+ mBC: DESTINY-Breast04 Trial
Author(s)Sponsored Content
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Balance Exercises for Patients With Cancer: How the Single-Leg Stand Builds Stability
2
Wildfire Smoke and Cancer Risk: What Patients Should Know
3
Clock Touches: An Advanced Balance Exercise for Patients with Cancer
4
A New Chapter in Prostate Cancer Care: How Focal Cryotherapy Is Changing the Game
5